Skip to main content
. 2021 Sep 15;12:743022. doi: 10.3389/fimmu.2021.743022

Table 2.

Potential biomarkers of disease severity in COVID-19.

Analytes Changes Role Ref
IL-1, IL-2, IL-6, TNF-a, G-CSF, GM-CSF, IFN-γ Increase Cytokine storm biomarker (102)
CD3+, CD4+, CD8+, B cells, NK cells Decrease Clinical Hematological biomarker (103)
CK, CK-MB, CRP, Ferritin, LDH, BUN, Creatinine, cTnI, AST, ALT, Total bilirubin Increase Clinical Biochemical biomarker (104)

IL, interleukin; TNF-a, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; IFN-γ, interferon gamma; NK, natural killer; CK, creatine kinase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; cTnI, cardiac troponin I; AST, aspartate aminotransferase; ALT, alanine aminotransferase.